ResMed shares are trading lower following sleep apnea data from Lilly.
Portfolio Pulse from Benzinga Newsdesk
ResMed shares are trading lower following sleep apnea data from Lilly.
June 24, 2024 | 1:14 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
ResMed shares are trading lower due to new sleep apnea data from Lilly, which may impact ResMed's market position in the sleep apnea treatment space.
The new sleep apnea data from Lilly could pose a competitive threat to ResMed, leading to a decline in its stock price as investors react to potential market share loss.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100